Second chance: could a repeat Clot-Buster save stroke patients?

NCT ID NCT07375953

Recruiting now Disease control Sponsor: General Hospital of Shenyang Military Region Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether giving a second dose of the clot-busting drug tenecteplase can help stroke patients who don't get better within an hour of the first dose. About 120 adults with acute ischemic stroke will receive either a second dose or standard care. The goal is to see if the extra dose is safe and improves recovery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tenecteplase (a clot-busting drug)
What this could lead to: If it works, this could offer a rescue treatment for stroke patients who don't respond to the first clot-busting drug, potentially reducing disability.
What could go wrong: This is a small, early-phase trial (120 people) testing safety and feasibility. The second dose may increase bleeding risk, and results may not apply to all stroke patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ISCHEMIC STROKE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ischemic stroke

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ISCHEMIC STROKE

Contacts and locations

Locations

Yu Cui
RECRUITING

Shenyang, None Selected, 110840, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.